BLINCYTO

Amgen Canada Inc🇨🇦 Health Canada

Approval Id: edf5161830bdf9a3
Drug Approval Canada Name: BLINCYTO
Product Name: BLINCYTO
Status: Marketed
Status Date: 2016-03-17
Original Market Date: 2016-03-17
Din: 02450283
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Prescription , Schedule D
Ahfs: 10:00.00
Atc Original: L01FX07 BLINATUMOMAB
Atc Name: l 01 fx 07
Aig Number: 0157670001
Company Name: Amgen Canada Inc
Company Address: 300, 6775 Financial Drive, Mississauga, Ontario, Canada, L5N 0A4

BLINATUMOMAB

38.5 MCG / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

edf5161830bdf9a3

Type

Standard